Abstract Objectives: To analyse perioperative and midterm outcomes of carotid artery stenting (CAS) for symptomatic >50% and asymptomatic >70% restenosis after open carotid surgery (OCS). Design: A multicentric retrospective study. Methods: Outcome measures 30-day death, neurologic and anatomic (thrombosis, restenosis) events. Univariant and multivariant logistic regression analyses were performed to identify predictive factors for neurologic and anatomic events. Results: A total of 249 patients with a mean age of 69 years (range, 45e88) were treated for asymptomatic (86%) or symptomatic (14%) restenosis. The 30-day combined operative mortality and stroke morbidity was 2.8% in asymptomatic patients and 2.9% in symptomatic patients. Events during follow-up (mean duration, 29 months) included stroke in four cases, TIA in two, stent thrombosis in four and restenosis in 21. KaplaneMeier estimates of overall survival, neurologic-event-free survival, anatomic-event-free survival and reinterventionfree survival were 95.4%, 94.7%, 96.7% and 99.5%, respectively, at 1 year and 80.3%, 93.8%, 85.1% and 96%, respectively, at 4 years. Multivariant analysis showed that statin use was correlated with a lower risk of anatomic events (odds ratio (OR) Z 0.15 (95% confidence interval (CI) 0.03e0.68), p Z 0.01) and that bypass was associated with a higher risk of anatomic events than endarterectomy (OR Z 5.0 (95% CI 1.6e16.6), p Z 0.009).
Conclusion: CAS is a feasible therapeutic alternative to OCS for carotid restenosis with acceptable risks in the perioperative period. Restenosis rate may be higher in patients treated after bypass. ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Reports describing long-term follow-up after carotid endarterectomy (CEA) indicate that restenosis with >50% diameter reduction occurs in 6e37% of patients. 1e3 However, accompanying neurological events have been reported in only 1e5% of these patients, 4e6 raising doubt as to the benefit of treating asymptomatic restenosis. Since the late 1990s, endovascular management of restenosis >50% has been proposed as an alternative to re-operation based on the rationale that redo open carotid surgery (OCS) under local anaesthesia is challenging and technically more difficult than CEA due to scar tissue that increases the risk of cranial nerve injury and hinders control of the internal carotid artery in case of extensive lesions. 7 According to Recommendation 5 of the European Society For Vascular Surgery (ESVS) guidelines regarding treatment for carotid stenosis, 8 carotid artery stenting (CAS) represents an alternative to redo CEA provided that the peri-interventional stroke risk is <3%. To improve decision making, this multicentric retrospective study was carried out to analyse 30-day and midterm outcomes of CAS for restenosis after OCS at 20 vascular surgery departments in France and Belgium.
Material and Methods

Study population
This retrospective study included patients who underwent CAS for restenosis following CEA or carotid artery bypass between January 1998 and July 2007 at 20 French and Belgian vascular surgery departments with experience in both OCS and CAS. Restenosis was defined as a diameter reduction >50% measured by duplex scan and/or computed tomography (CT) angiography. Indications for CAS in patients with restenosis were symptomatic >50% and asymptomatic >70% restenosis. Medical charts were reviewed to extract demographic data, restenosis characteristics and medications used. Details concerning the CAS procedure, including type of cerebral protection device and stent, were also noted. Patient selection for CAS was at the discretion of each practitioner based on clinical experience, anatomic features affecting CAS feasibility, for example, hostile aortic arch and contraindications for general anaesthesia for redo CEA. None of the patients included in this study was previously included in the EVA-3S trial. 9 This study was approved by the Institutional Review Boards of each participating department. The number of patients with restenosis who were not treated during the study period was undeterminable.
Operative technique
Arterial access was achieved using the transfemoral approach. After administering an intravenous bolus of heparin (50 UI/kg), the common carotid artery was cannulated using an 8-F guiding catheter with 0.035-Terumo guidewire and selective carotid angiography was performed to re-assess the degree of restenosis and intracranial circulation. The 0.035-guidewire was then replaced with a 0.014-guidewire to facilitate passage through the stenosis. Predilatation was performed in case of high-grade stenosis. In recent years, placement of a cerebral protection device has become routine. After deployment, the stent was expanded using a balloon catheter. In some cases treated at the beginning of the study, dilatation of restenosis was not followed by stent placement. Completion angiography was performed to determine the degree of residual stenosis. Atropin was used selectively. Anti-platelet therapy with at least one drug was administered before and after intervention.
Follow-up
None of the participating centres performed independent neurologic assessment. Diagnosis of myocardial infarction (MI) was based on the elevated troponin level measured after chest pain, electrocardiogram (EKG) modification or, in some centres, systematically. All patients underwent post-procedural duplex scanning within 7 days and at 3e6 months, depending on the policy of each centre. The interval between consecutive follow-up examinations with duplex scans generally ranged from 6 to 12 months. In the last years of the study, specific duplex criteria were used to estimate intrastent restenosis: internal carotid artery/ common carotid artery ratio >2.7 and peak systolic velocity 220e339 cm s À1 predict 50e79% stenosis, internal carotid artery/common carotid artery ratio >4.15 and peak systolic velocity >340 cm s À1 predict 80% stenosis.
Definitions and end points
The degree of stenosis was assessed by CT angiography according to criteria defined by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) trial. 10 Procedures were considered as technical successes if stent deployment was achieved and if residual stenosis was less than 20% after the procedure. Primary study outcomes were 30-day postoperative death, neurologic event (transient ischaemia attack (TIA) or stroke) and anatomic events (restenosis or occlusion). Restenosis following CAS was defined as greater than 50% narrowing measured by duplex scan. Stroke was defined as neurologic manifestations persisting more than 24 h and TIA was defined as neurologic manifestations resolving within 24 h. Neurologic events were classified as ipsilateral if they affected the cerebral hemisphere on the same side as the carotid stent and contralateral if they affected the cerebral hemisphere on the opposite side from the carotid stent.
Data analysis and statistical methods
All variables were expressed as means AE standard deviation (SD) or as numeric values (%). KaplaneMeier curves were constructed to estimate overall survival, neurologic-eventfree survival, anatomic-event-free survival and reinterventionfree survival. Univariant analysis and multivariant logistic regression analysis were performed to identify predictive factors for neurologic and anatomic events. Risk factors included in the analysis were age, gender, cardiovascular history, vascular risk factors (diabetes, hypertension, hypercholesterolaemia and smoking), interval between the first carotid surgery and CAS (more or less than 2 years following OCS), location of stenosis, degree of stenosis, symptomatic vs. asymptomatic stenosis, contralateral carotid disease, stent type (Wallstent (Boston Scientific, Natick, MA, USA) vs. other), use of cerebral protection device, use of statins before and after CAS and anti-platelet regimen. A probability value of p < 0.05 was considered statistically significant.
Results
The charts of 249 patients who underwent CAS for restenosis after OCS at 20 vascular surgery departments from January 1998 to July 2007 were retrospectively analysed. At time of CAS, restenosis was asymptomatic in 214 patients (86%) and symptomatic in 35 patients (14%). Patient data and restenosis characteristics are shown in Table 1 . Mean degree of restenosis was 82.4 AE 8% (60e95%) in symptomatic patients and 82.4 AE 7% (70e95%) in asymptomatic patients. Out the 214 asymptomatic restenosis, 36 (17%) were between 70% and 80%. The mean interval between OCS and CAS for restenosis was 43.4 months (range, 1e264). A total of 121 patients (48.6%) underwent CAS within 2 years after OCS. Procedural details are presented in Table 2 . Aortic arch anatomy was documented in 173 cases; it was type I in 49.7%, type II in 29.5% and type III in 20.8%. At the end of the study, cerebral protection devices were used routinely as per recommendations of the steering committee of the EVA-3S trial. 9 Preoperative and postoperative medications are listed in Table 3 . Before 2003, patients were given aspirin alone or with ticlopidin. From 2003 until the end of study, almost all patients received aspirin and clopidogrel starting at least 48 h before the procedure and continuing for 1 month thereafter. Treatment was then reduced to a single antiplatelet agent. In the subgroup of 28 patients presenting restenosis following bypass surgery, narrowing was symptomatic in five cases (18%). The bypass was from the common carotid artery to internal carotid artery. A prosthetic graft was used in 12 cases (43%). Restenosis was located at the proximal anastomosis in eight cases (29%), distal anastomosis in 18 (64%) and mid-bypass in two (7%). The mean interval between bypass and CAS for restenosis was 27.7 months (range, 1e84). The procedure was performed under general anaesthesia in five cases (18%) and required the use of an embolic protection device in 10 (36%).
Thirty-day outcome
The technical success rate was 99.6%. The one failure occurred in a patient who presented a bovine arch preventing catheterisation of the common carotid artery and developed stroke. No residual stenosis was observed. In one symptomatic and eight asymptomatic patients including the previous patient, neurologic events, that is, seven strokes and 2 TIAs that were all ipsilateral, were observed during the postoperative period (Table 4 ). In two of these cases, completion angiography depicted abnormal findings, that is, distal dissection equiring emergency saphenous vein bypass grafting in a patient who developed stroke and stent thrombus despite aspiration in a patient who developed TIA. No patient developed MI. The 30-day combined stroke and death rate (CSDR) was 2.8% in asymptomatic patients and 2.9% in symptomatic patients (Table 5 ). In the group of patients that did not develop neurologic complication following technically successful CAS, there were two complications, that is, vasospasm that was resolved by direct nitroprussiate injection and dissection of the common carotid artery that was successfully treated by stent placement. Additional postoperative morbidity included groin haematoma in two cases and false aneurysm of the femoral artery in three, including one requiring surgical revision.
Long-term outcome
Mean follow-up was 29 months (range, 1e156). Four patients were lost to follow-up. Thirty patients died during the study period. Causes of death included cardiovascular disease in nine cases, cancer in seven, respiratory insufficiency in three, colonic ischaemia in one and unknown causes in seven. In the remaining three cases, death was due to neurologic events, that is, ipsilateral stroke in the postoperative period, haemorrhagic stroke following thrombolysis for limb ischaemia and ischaemic ipsilateral stroke at 14 months with the last follow-up duplex scan showing normal carotid flow. A total of six neurological events occurred (Table 6 ). In three of these patients, the event was related to stent thrombosis at 2, 5 and 24 months. In one patient, high-grade restenosis (80%) was treated by repeat CAS at 61 months with no complications at 11 months of follow-up. In the remaining two cases, including the late fatal stroke, duplex scans were normal. Follow-up duplex scan detected asymptomatic stent occlusion at 6 months in one patient and asymptomatic restenosis in 20 patients (Table 7) . Six asymptomatic restenosis !70% were treated by repeat angioplasty with no complications. The rate of anatomic events during the 29-months of follow-up period was 10% overall, 9.7% in the asymptomatic group and 11.4% in the symptomatic group (Table 8) . KaplaneMeier estimates of overall survival, neurologic-event-free survival, anatomic-event-free survival and reintervention-free survival were 95.4%, 94.7%, 96.7% and 99.5%, respectively, at 1 year and 80.3%, 93.8%, 85.1% and 96%, respectively, at 4 years (Figs. 1e4) .
Univariant and multivariant analysis
The location of the stenosis, that is, involving the common or internal carotid artery, was not predictive for neurologic or anatomic events. Univariant analysis identified no predictive factors for postoperative neurologic events. Conversely, multivariant analysis demonstrated an independent correlation between symptomatic restenosis and risk of delayed neurologic events (odds ratio (OR) Z 14 (95% confidence interval (CI) 2.5.14e79.8), p Z 0.003). Multivariant analysis also found that statins lowered the risk of anatomic events following CAS (OR Z 0.15 (95% CI 0.03e0.68), p Z 0.01) and that the risk of anatomic events was higher after bypass than endarterectomy (OR Z 5.0 (95% CI 1.6e16.6), p Z 0.009). 
Discussion
The indication for treatment of restenosis following OCS is widely accepted for symptomatic patients with narrowing >50%, but treatment for asymptomatic patients remains controversial. In one recent review, Lal 7 reported a low complication rate after CAS and suggested 80% narrowing as a threshold for considering treatment in asymptomatic patients. In our study, the mean diameter of restenosis was 82%, and only 36 patients (17%) were asymptomatic between 70% and 80%. By the end of this study, most of the participating centres had adopted the 80% threshold value for treatment of asymptomatic carotid restenosis.
Regarding 30-day outcomes in this study, the absence of postoperative MI is intriguing. This occurred even though coronary artery disease was present in one-third of the patients and cardiovascular events accounted for 9 of the 23 deaths during follow-up. A possible explanation is that only 14% of the CAS procedures required general anaesthesia. This view is in agreement with the results of the recent Carotid Revascularization Endarterctomy versus Stenting Trial (CREST) trial 11 that showed a lower early MI rate after CAS than OCS: 1.1% versus 2.3% (p Z 0.03). In the CREST trial, 90% of OCS procedures were performed under general anaesthesia.
With a 30-day CSDR of 2.8% in patients with asymptomatic restenosis and 2.9% in patients with symptomatic restenosis, the 3% condition set for use of CAS by the ESVS recommendation 8 was met in our study. For comparison, In these series, the CSDR ranged from 0% to 5.9%. In the largest series, that is, White et al. 24 based on a national registry, the CSDR was 3.8% in the 341 asymptomatic patients but rose to 5.9% in the 188 symptomatic patients.
By analysing the embolic load in cerebral protection devices, Malik et al. 25 showed that restenosis after CEA was associated with minimal embolic generation in comparison with primary stenosis and concluded that systematic use of protection devices was not necessary during CAS for restenosis. Regarding endovascular treatment of primary carotid stenosis, the benefit of cerebral protection is still poorly documented as specified in ESVS recommendations. 8 The risk of embolisation is presumably higher in association with arteriosclerotic disease that is the most common cause of late restenosis than with myointimal hyperplasia. 7, 26 In a study focussing on the embolic load in cerebral protection devices used during CAS for restenosis, Vos et al. 22 found no significant difference between patients treated for early versus late restenosis. No correlation was found with the delay between primary carotid revascularisation and CAS performed for restenosis at more or less than 2 years after OCS.
A frequent statement echoed by physicians reluctant to use CAS is that endovascular treatment is associated with a higher incidence of late anatomic events, that is, restenosis and thrombosis. As in our experience, recent series 27e29 describing OCS for restenosis after primary surgical revascularisation have reported anatomic-event rates ranging from 7.5% to 16%. In this regard, some studies 30e32 have shown that the use of native-artery velocity criteria in stented arteries leads to overestimation of the degree of restenosis. Several authors 32 have proposed revised duplex velocity criteria for grading stenosis in stented arteries and it is now generally accepted that an internal/common carotid artery ratio >4.15 and peak systolic velocity >340 cm s À1 are predictive of 80% narrowing. By the end of our study, most participating centres were using these criteria.
Our multivariant analysis indicated that the risk of anatomic events was higher after carotid bypass than endarterectomy (OR Z 5.0 (95% CI 1.6e16.6), p Z 0.009). This correlation between bypass and anatomic events is 33 who reported a 14% incidence of severe recurrent stenosis or occlusion within 18 months after vein grafting and with the lower complication rates reported by surgeons preferring synthetic grafts. 34 This suggests that enhanced duplex scan surveillance is necessary in patients who undergo CAS for restenosis following carotid bypass especially using vein grafts.
Regarding postoperative medication, 75% of the occlusions observed in our study occurred within 6 months after CAS and dual-agent anti-platelet therapy had been prescribed postoperatively in only one of these three cases. At the end of our study, every patient underwent postoperative dual-agent anti-platelet therapy for at least 1 month. The ESVS guidelines 8 state that dual-agent antiplatelet therapy is mandatory for at least 3 months. Although the use of postoperative statins increased during the course of our study, they were prescribed in only onethird of patients. In a retrospective review of CAS for high-grade symptomatic stenosis, Groschel et al. 35 observed that postoperative statins reduce the overall incidence of cardiovascular events. Furthermore, Verzini et al. 36 showed that statin use is associated with a lower risk of perioperative and late ischaemic stroke and reduced mortality rate. Although we did not observe this difference, our multivariant analysis showed that postoperative statin medication lowered the risk of anatomic events (OR Z 0.15 (95% CI 0.03e0.68)).
The main limitations of this study are its retrospective design with data collection from medical charts and the lack of independent neurologic assessment. Our early outcomes were good despite the fact that these procedures coincided with the beginning of the CAS learning curve for the participating surgeons. Caution is necessary in interpreting this high technical success rate as OCS was preferred to CAS in patients with challenging anatomy during the early period of this study. Due to the low incidence of postoperative death and neurologic events, univariant analysis was unable to identify risk factors for 30-day morbidity/mortality. Regarding midterm outcomes, multivariant analysis detected an independent correlation between symptomatic restenosis and the risk of delayed stroke or TIA (OR Z 14 (95% CI 2.46e79.8), p Z 0.003), even though this complication occurred in only six patients in our series (Table 6 ). These findings should be confirmed by a randomised prospective control study with welldefined anatomic criteria of symptomatic and possibly high-grade asymptomatic carotid restenosis.
This study demonstrates that CAS is a feasible therapeutic alternative to OCS for carotid restenosis with acceptable risks in the 30-day postoperative period. The restenosis rate may be higher in those presenting restenosis after bypass, thus justifying enhanced duplex scan surveillance. 
